Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
JS

NASDAQ · JSPR

Jasper Therapeutics, Inc.

Healthcare · Biotechnology

$0.52

Down-$0.01 (-2.22%)

Updated Nov 1, 2026, 8:59 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.9M
P/E ratio
-0.43
Dividend yield
0.00%
52-week range
$0.32 – $2.48
Volume
396.13K
Avg. volume
1.49M

Price performance · JSPR

JSPR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

JSPR closed at $0.52 after 20 trading sessions, down 12.25% for the selected period.

Last close
$0.52
Period change
-12.25%
Period low
$0.48
Period high
$0.59
Daily close
View OHLC price history
JSPR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.516$0.554$0.5106$0.5202396.13K
Oct 29, 2026$0.5331$0.5632$0.511$0.532413.08K
Oct 28, 2026$0.5001$0.5481$0.5001$0.5388371.17K
Oct 27, 2026$0.4766$0.53$0.4601$0.51891.32M
Oct 26, 2026$0.51$0.521$0.4952$0.5054396.74K
Oct 23, 2026$0.4956$0.5398$0.4839$0.51323.72K
Oct 22, 2026$0.50$0.5146$0.49$0.495672.34K
Oct 21, 2026$0.52$0.5399$0.497$0.5043358.79K
Oct 20, 2026$0.4775$0.5285$0.4767$0.4999366.54K
Oct 19, 2026$0.47$0.4902$0.46$0.4774391.72K
Oct 16, 2026$0.546$0.55$0.4778$0.4799246.4K
Oct 15, 2026$0.49$0.5447$0.4755$0.5321381.31K
Oct 14, 2026$0.5012$0.5169$0.4601$0.501620.11K
Oct 13, 2026$0.54$0.54$0.4956$0.4956429.84K
Oct 12, 2026$0.5688$0.577$0.5446$0.555335.8K
Oct 9, 2026$0.5469$0.5774$0.541$0.5702261.89K
Oct 8, 2026$0.5626$0.58$0.5403$0.56362.71K
Oct 7, 2026$0.5433$0.59$0.5401$0.5697365.54K
Oct 6, 2026$0.60$0.60$0.55$0.5601328.61K
Oct 5, 2026$0.57$0.5959$0.542$0.5928376.09K

Latest JSPR news

The latest Smart Investors Daily articles mentioning JSPR.

Stock researchCompany · Overview

JSPR research

Overview

Company profile and research snapshot.

Company profile

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.67
Implied upside
—
Analysts
—
JSPR recent ratings
DateFirmRatingTarget
Oct 14, 2026William BlairOutperform—
Aug 12, 2026Piper SandlerOverweight—
May 15, 2026TD CowenHold—
May 15, 2026RBC CapitalSector Perform—
Apr 1, 2026Evercore ISI GroupOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed e

Yahoo · Oct 7, 2026

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in its underwritten

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By